GRCE
HEALTHCAREGrace Therapeutics, Inc.
AI Insight
What's Moving GRCE Today?
No stock-specific AI insight has been generated for GRCE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.79$5.18
$2.34
Fundamentals
Market Cap$37M
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-11.9%
Profit Margin—
Debt / Equity—
Trading
Volume131K
Avg Volume (10D)—
Shares Outstanding16.3M
GRCE News
20 articles- Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateYahoo Finance·Jun 18, 2026
- Sector Update: Health Care Stocks Edge Lower Late AfternoonYahoo Finance·Apr 23, 2026
- Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104Yahoo Finance·Apr 23, 2026
- Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026GlobeNewswire Inc.·Apr 14, 2026
- We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn RateYahoo Finance·Apr 4, 2026
- Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesYahoo Finance·Mar 19, 2026
- Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateYahoo Finance·Feb 12, 2026
- Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferenceYahoo Finance·Nov 17, 2025
- Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business UpdateYahoo Finance·Nov 13, 2025
- Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual MeetingYahoo Finance·Nov 11, 2025
- This Grace Therapeutics Insider Increased Their Holding By 12% Last YearYahoo Finance·Nov 1, 2025
- Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA ReviewYahoo Finance·Oct 23, 2025
- We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth CarefullyYahoo Finance·Sep 23, 2025
- Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual MeetingYahoo Finance·Sep 22, 2025
- Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104Yahoo Finance·Sep 18, 2025
- Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 4, 2025
- Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104Yahoo Finance·Aug 27, 2025
- GRCE: Looking Ahead to AcceptanceYahoo Finance·Aug 13, 2025
- Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business UpdateYahoo Finance·Aug 12, 2025
All 20 articles loaded
Price Data
Open$2.41
Previous Close$2.39
Day High$2.48
Day Low$2.31
52 Week High$5.18
52 Week Low$1.79
52-Week Range
$1.79$5.18
$2.34
Fundamentals
Market Cap$37M
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-11.9%
Profit Margin—
Debt / Equity—
Trading
Volume131K
Avg Volume (10D)—
Shares Outstanding16.3M
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in Princeton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—